Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/ski-g-801-an-axl-kinase-inhibitor-blocks-metastasis-through-inducing-ZsWMhEtk18
References (75)
-
Xiaoliang Wu, Wen-juan Ma, Qianghua Zhou, H. Yan, Zuan-Fu Lim, Mayan Huang, Chuangzhong Deng, Xingsu Yu, Huifang Su, S. Komo, Haixia Yang, Xinke Zhang, S. Wen, Zhenfeng Zhang, P. Ma (2017)
AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastasesJournal of Cancer Research and Clinical Oncology, 143
-
J. Reiser, A. Banerjee (2016)
Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune ResponseJournal of Immunology Research, 2016
-
Willy Hugo, J. Zaretsky, Lu Sun, Chunying Song, B. Moreno, S. Hu-Lieskovan, B. Berent-Maoz, Jia Pang, B. Chmielowski, Grace Cherry, E. Seja, Shirley Lomeli, X. Kong, M. Kelley, J. Sosman, Douglas Johnson, A. Ribas, R. Lo (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 168
-
( Zhang G , Wang M , Zhao H , Cui W . Function of AXL receptor tyrosine kinase in non‐small cell lung cancer. Oncol Lett 2018; 15: 2726–2734.29434997)
Zhang G , Wang M , Zhao H , Cui W . Function of AXL receptor tyrosine kinase in non‐small cell lung cancer. Oncol Lett 2018; 15: 2726–2734.29434997Zhang G , Wang M , Zhao H , Cui W . Function of AXL receptor tyrosine kinase in non‐small cell lung cancer. Oncol Lett 2018; 15: 2726–2734.29434997, Zhang G , Wang M , Zhao H , Cui W . Function of AXL receptor tyrosine kinase in non‐small cell lung cancer. Oncol Lett 2018; 15: 2726–2734.29434997
-
P. Forde, J. Chaft, Kellie Smith, V. Anagnostou, T. Cottrell, M. Hellmann, M. Zahurak, Stephen Yang, David Jones, S. Broderick, R. Battafarano, M. Velez, N. Rekhtman, Zachary Olah, J. Naidoo, K. Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, Justina Caushi, H. Chan, John-William Sidhom, R. Scharpf, J. White, E. Gabrielson, Hao Wang, G. Rosner, V. Rusch, J. Wolchok, T. Merghoub, J. Taube, V. Velculescu, S. Topalian, J. Brahmer, D. Pardoll (2018)
Neoadjuvant PD‐1 Blockade in Resectable Lung CancerThe New England Journal of Medicine, 378
-
( Collett G , Wood A , Alexander MY et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 2003; 92: 1123–1129.12730092)
Collett G , Wood A , Alexander MY et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 2003; 92: 1123–1129.12730092Collett G , Wood A , Alexander MY et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 2003; 92: 1123–1129.12730092, Collett G , Wood A , Alexander MY et al. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 2003; 92: 1123–1129.12730092
-
N. Syn, M. Teng, T. Mok, R. Soo (2017)
De-novo and acquired resistance to immune checkpoint targeting.The Lancet. Oncology, 18 12
-
Yun-Jung Choi, Ji Kim, J. Rho, Joong Kim, Chang-Min Choi, W. Kim, J. Son, Jae Lee (2018)
AXL and MET receptor tyrosine kinases are essential for lung cancer metastasisOncology Reports, 41
-
Jing Liu, S. Blake, M. Yong, Heidi Harjunpää, S. Ngiow, K. Takeda, A. Young, Jake O’Donnell, Stacey Allen, M. Smyth, M. Teng (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.Cancer discovery, 6 12
-
( Yi Z , Gan‐Lin Z , Xu S et al. Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncol Lett 2018; 15: 6233–6240.29616105)
Yi Z , Gan‐Lin Z , Xu S et al. Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncol Lett 2018; 15: 6233–6240.29616105Yi Z , Gan‐Lin Z , Xu S et al. Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncol Lett 2018; 15: 6233–6240.29616105, Yi Z , Gan‐Lin Z , Xu S et al. Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncol Lett 2018; 15: 6233–6240.29616105
-
L. Zucca, Mariana Matushita, Renato Oliveira, C. Scapulatempo-Neto, M. Lima, G. Ribeiro, C. Viana, F. Carcano, R. Reis (2018)
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.Urologic oncology, 36 1
-
Marlies Peeters, Anne Rahbech, P. Straten (2019)
TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targetingCancer Immunology, Immunotherapy, 69
-
Jane Antony, R. Huang (2017)
AXL-Driven EMT State as a Targetable Conduit in Cancer.Cancer research, 77 14
-
( Yu H , Liu R , Ma B et al. AXL receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 2015; 113: 616–625.26180925)
Yu H , Liu R , Ma B et al. AXL receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 2015; 113: 616–625.26180925Yu H , Liu R , Ma B et al. AXL receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 2015; 113: 616–625.26180925, Yu H , Liu R , Ma B et al. AXL receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 2015; 113: 616–625.26180925
-
( Elvin P , Garner AP . Tumor invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 2005; 5: 374–381.15955738)
Elvin P , Garner AP . Tumor invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 2005; 5: 374–381.15955738Elvin P , Garner AP . Tumor invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 2005; 5: 374–381.15955738, Elvin P , Garner AP . Tumor invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 2005; 5: 374–381.15955738
-
Yi Zhang, Gan‐Lin Zhang, Xu Sun, Ke-xin Cao, Cong Ma, Nan Nan, Guowang Yang, Mingwei Yu, Xiaomin Wang (2018)
Establishment of a murine breast tumor model by subcutaneous or orthotopic implantationOncology Letters, 15
-
Writing -original draft; Writing -review & editing -
( Aguilera TA , Rafat M , Castellini L et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun 2016; 7: 13898.28008921)
Aguilera TA , Rafat M , Castellini L et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun 2016; 7: 13898.28008921Aguilera TA , Rafat M , Castellini L et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun 2016; 7: 13898.28008921, Aguilera TA , Rafat M , Castellini L et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun 2016; 7: 13898.28008921
-
Manikandan Subramanian, C. Hayes, J. Thome, E. Thorp, G. Matsushima, J. Herz, D. Farber, Kang Liu, M. Lakshmana, I. Tabas (2014)
An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo.The Journal of clinical investigation, 124 3
-
( Syn NL , Teng MWL , Mok TSK , Soo RA . De‐novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18: e731–e741.29208439)
Syn NL , Teng MWL , Mok TSK , Soo RA . De‐novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18: e731–e741.29208439Syn NL , Teng MWL , Mok TSK , Soo RA . De‐novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18: e731–e741.29208439, Syn NL , Teng MWL , Mok TSK , Soo RA . De‐novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18: e731–e741.29208439
-
( Hasanbasic I , Cuerquis J , Varnum B , Blostein MD . Intracellular signaling pathways involved in Gas6‐Axl‐mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287: H1207–H1213.15130893)
Hasanbasic I , Cuerquis J , Varnum B , Blostein MD . Intracellular signaling pathways involved in Gas6‐Axl‐mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287: H1207–H1213.15130893Hasanbasic I , Cuerquis J , Varnum B , Blostein MD . Intracellular signaling pathways involved in Gas6‐Axl‐mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287: H1207–H1213.15130893, Hasanbasic I , Cuerquis J , Varnum B , Blostein MD . Intracellular signaling pathways involved in Gas6‐Axl‐mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287: H1207–H1213.15130893
-
( Skinner HD , Giri U , Yang LP et al. Integrative analysis identifies a novel AXL‐PI3 kinase‐PD‐L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 2017; 23: 2713–2722.28476872)
Skinner HD , Giri U , Yang LP et al. Integrative analysis identifies a novel AXL‐PI3 kinase‐PD‐L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 2017; 23: 2713–2722.28476872Skinner HD , Giri U , Yang LP et al. Integrative analysis identifies a novel AXL‐PI3 kinase‐PD‐L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 2017; 23: 2713–2722.28476872, Skinner HD , Giri U , Yang LP et al. Integrative analysis identifies a novel AXL‐PI3 kinase‐PD‐L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 2017; 23: 2713–2722.28476872
-
Hsin-Jung Lee, Y. Jeng, Yu‐Ling Chen, L. Chung, Ray-Hwang Yuan (2014)
Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.Carcinogenesis, 35 4
-
( Tai KY , Shieh YS , Lee CS , Shiah SG , Wu CW . Axl promotes cell invasion by inducing MMP‐9 activity through activation of NF‐kappaB and Brg‐1. Oncogene 2008; 27: 4044–4055.18345028)
Tai KY , Shieh YS , Lee CS , Shiah SG , Wu CW . Axl promotes cell invasion by inducing MMP‐9 activity through activation of NF‐kappaB and Brg‐1. Oncogene 2008; 27: 4044–4055.18345028Tai KY , Shieh YS , Lee CS , Shiah SG , Wu CW . Axl promotes cell invasion by inducing MMP‐9 activity through activation of NF‐kappaB and Brg‐1. Oncogene 2008; 27: 4044–4055.18345028, Tai KY , Shieh YS , Lee CS , Shiah SG , Wu CW . Axl promotes cell invasion by inducing MMP‐9 activity through activation of NF‐kappaB and Brg‐1. Oncogene 2008; 27: 4044–4055.18345028
-
Guoan Zhang, Meng Wang, Hongli Zhao, W. Cui (2017)
Function of Axl receptor tyrosine kinase in non-small cell lung cancer.Oncology letters, 15 3
-
Byoung Chul Cho: Data curation; Formal analysis; Funding acquisition; Investigation -
( Brand TM , Iida M , Stein AP et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21: 2601–2612.25767293)
Brand TM , Iida M , Stein AP et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21: 2601–2612.25767293Brand TM , Iida M , Stein AP et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21: 2601–2612.25767293, Brand TM , Iida M , Stein AP et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21: 2601–2612.25767293
-
H. Skinner, U. Giri, Liangpeng Yang, Manish Kumar, Y. Liu, M. Story, C. Pickering, L. Byers, M. Williams, Jing Wang, Li Shen, S. Yoo, Youhong Fan, D. Molkentine, B. Beadle, R. Meyn, J. Myers, J. Heymach (2017)
Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck CancerClinical Cancer Research, 23
-
K. Tai, Y. Shieh, C. Lee, S. Shiah, C-W Wu (2008)
Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1Oncogene, 27
-
Wei‐Ping Lee, Y. Wen, B. Varnum, M. Hung (2002)
Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosisOncogene, 21
-
( Scheele CLGJ , Maynard C , van Rheenen J . Intravital insights into heterogeneity, metastasis, and therapy responses. Trends Cancer 2016; 2: 205–216.28741572)
Scheele CLGJ , Maynard C , van Rheenen J . Intravital insights into heterogeneity, metastasis, and therapy responses. Trends Cancer 2016; 2: 205–216.28741572Scheele CLGJ , Maynard C , van Rheenen J . Intravital insights into heterogeneity, metastasis, and therapy responses. Trends Cancer 2016; 2: 205–216.28741572, Scheele CLGJ , Maynard C , van Rheenen J . Intravital insights into heterogeneity, metastasis, and therapy responses. Trends Cancer 2016; 2: 205–216.28741572
-
( D'Alfonso TM , Hannah J , Chen Z , Liu Y , Zhou P , Shin SJ . AXL receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014; 67: 690–696.24904064)
D'Alfonso TM , Hannah J , Chen Z , Liu Y , Zhou P , Shin SJ . AXL receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014; 67: 690–696.24904064D'Alfonso TM , Hannah J , Chen Z , Liu Y , Zhou P , Shin SJ . AXL receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014; 67: 690–696.24904064, D'Alfonso TM , Hannah J , Chen Z , Liu Y , Zhou P , Shin SJ . AXL receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014; 67: 690–696.24904064
-
G. Collett, A. Wood, M. Alexander, B. Varnum, R. Boot-Handford, V. Ohanian, J. Ohanian, Y. Fridell, A. Canfield (2003)
Receptor Tyrosine Kinase Axl Modulates the Osteogenic Differentiation of PericytesCirculation Research: Journal of the American Heart Association, 92
-
Fang Wu, Junhe Li, C. Jang, Janfeng Wang, J. Xiong (2014)
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.International journal of clinical and experimental pathology, 7 10
-
Project administration; Resources; Software; Supervision -
( Yang S , Zhang JJ , Huang XY . Mouse models for tumor metastasis. Methods Mol Biol 2012; 928: 221–228.22956145)
Yang S , Zhang JJ , Huang XY . Mouse models for tumor metastasis. Methods Mol Biol 2012; 928: 221–228.22956145Yang S , Zhang JJ , Huang XY . Mouse models for tumor metastasis. Methods Mol Biol 2012; 928: 221–228.22956145, Yang S , Zhang JJ , Huang XY . Mouse models for tumor metastasis. Methods Mol Biol 2012; 928: 221–228.22956145
-
T. Aguilera, M. Rafat, Laura Castellini, Hussein Shehade, Mihalis Kariolis, A. Hui, H. Stehr, R. Eyben, D. Jiang, L. Ellies, A. Koong, M. Diehn, E. Rankin, E. Graves, A. Giaccia (2016)
Reprogramming the immunological microenvironment through radiation and targeting AxlNature Communications, 7
-
( Zhou L , Liu X‐D , Sun M et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35: 2687–2697.26364599)
Zhou L , Liu X‐D , Sun M et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35: 2687–2697.26364599Zhou L , Liu X‐D , Sun M et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35: 2687–2697.26364599, Zhou L , Liu X‐D , Sun M et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35: 2687–2697.26364599
-
P. Schmid, R. Salgado, Yeon-Hee Park, E. Muñoz-Couselo, Sung-Bae Kim, J. Sohn, S. Im, T. Foukakis, S. Kuemmel, R. Dent, L. Yin, A. Wang, K. Tryfonidis, V. Karantza, J. Cortés, S. Loi (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.Annals of oncology : official journal of the European Society for Medical Oncology
-
T. Brand, M. Iida, Andrew Stein, K. Corrigan, Cara Braverman, J. Coan, Hannah Pearson, H. Bahrar, T. Fowler, B. Bednarz, Sandeep Saha, D. Yang, P. Gill, M. Lingen, V. Saloura, V. Villaflor, R. Salgia, R. Kimple, D. Wheeler (2015)
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 21
-
( Zhu C , Wei Y , Wei X . AXL receptor tyrosine kinase as a promising anticancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 2019; 18: 153.31684958)
Zhu C , Wei Y , Wei X . AXL receptor tyrosine kinase as a promising anticancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 2019; 18: 153.31684958Zhu C , Wei Y , Wei X . AXL receptor tyrosine kinase as a promising anticancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 2019; 18: 153.31684958, Zhu C , Wei Y , Wei X . AXL receptor tyrosine kinase as a promising anticancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 2019; 18: 153.31684958
-
( Liu J , Blake SJ , Yong MCR et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016; 6: 1382–1399.27663893)
Liu J , Blake SJ , Yong MCR et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016; 6: 1382–1399.27663893Liu J , Blake SJ , Yong MCR et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016; 6: 1382–1399.27663893, Liu J , Blake SJ , Yong MCR et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016; 6: 1382–1399.27663893
-
( Forde PM , Chaft JE , Smith KN et al. Neoadjuvant PD‐1 blockade in resectable lung cancer. N Engl J Med 2018; 378: 1976–1986.29658848)
Forde PM , Chaft JE , Smith KN et al. Neoadjuvant PD‐1 blockade in resectable lung cancer. N Engl J Med 2018; 378: 1976–1986.29658848Forde PM , Chaft JE , Smith KN et al. Neoadjuvant PD‐1 blockade in resectable lung cancer. N Engl J Med 2018; 378: 1976–1986.29658848, Forde PM , Chaft JE , Smith KN et al. Neoadjuvant PD‐1 blockade in resectable lung cancer. N Engl J Med 2018; 378: 1976–1986.29658848
-
( Peeters MJW , Rahbech A , Thor SP . TAM‐ing T cells in the tumor microenvironment: implications for TAM receptor targeting. Cancer Immunol Immunother 2020; 69: 237–244.31664482)
Peeters MJW , Rahbech A , Thor SP . TAM‐ing T cells in the tumor microenvironment: implications for TAM receptor targeting. Cancer Immunol Immunother 2020; 69: 237–244.31664482Peeters MJW , Rahbech A , Thor SP . TAM‐ing T cells in the tumor microenvironment: implications for TAM receptor targeting. Cancer Immunol Immunother 2020; 69: 237–244.31664482, Peeters MJW , Rahbech A , Thor SP . TAM‐ing T cells in the tumor microenvironment: implications for TAM receptor targeting. Cancer Immunol Immunother 2020; 69: 237–244.31664482
-
Haiyang Yu, Haiyang Yu, Ren Liu, Binyun Ma, Xiuqing Li, Hsuehheng Yen, Yue Zhou, V. Krasnoperov, Z. Xia, X. Zhang, X. Zhang, A. Bove, M. Buscarini, D. Parekh, I. Gill, Q. Liao, M. Tretiakova, D. Quinn, J. Zhao, P. Gill (2015)
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinomaBritish Journal of Cancer, 113
-
D. Graham, D. DeRyckere, K. Davies, H. Earp (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancerNature Reviews Cancer, 14
-
( Antony J , Huang RY . AXL‐driven EMT state as a targetable conduit in cancer. Cancer Res 2017; 77: 3725–3732.28667075)
Antony J , Huang RY . AXL‐driven EMT state as a targetable conduit in cancer. Cancer Res 2017; 77: 3725–3732.28667075Antony J , Huang RY . AXL‐driven EMT state as a targetable conduit in cancer. Cancer Res 2017; 77: 3725–3732.28667075, Antony J , Huang RY . AXL‐driven EMT state as a targetable conduit in cancer. Cancer Res 2017; 77: 3725–3732.28667075
-
( Gao L , Zhang C , Gao D et al. Enhanced anti‐tumor efficacy through a combination of integrin αvβ6‐targeted photodynamic therapy and immune checkpoint inhibition. Theranostics 2016; 6: 627–637.27022411)
Gao L , Zhang C , Gao D et al. Enhanced anti‐tumor efficacy through a combination of integrin αvβ6‐targeted photodynamic therapy and immune checkpoint inhibition. Theranostics 2016; 6: 627–637.27022411Gao L , Zhang C , Gao D et al. Enhanced anti‐tumor efficacy through a combination of integrin αvβ6‐targeted photodynamic therapy and immune checkpoint inhibition. Theranostics 2016; 6: 627–637.27022411, Gao L , Zhang C , Gao D et al. Enhanced anti‐tumor efficacy through a combination of integrin αvβ6‐targeted photodynamic therapy and immune checkpoint inhibition. Theranostics 2016; 6: 627–637.27022411
-
Shengyu Yang, Shengyu Yang, J. Zhang, Xin-Yun Huang (2012)
Mouse models for tumor metastasis.Methods in molecular biology, 928
-
Wongeun Lee: Data curation; Investigation -
( Wu F , Li J , Jang C , Wang J , Xiong J . The role of Axl in drug resistance and epithelial‐to‐mesenchymal transition of non‐small cell lung carcinoma. Int J Clin Exp Pathol 2014; 7: 6653–6661.25400744)
Wu F , Li J , Jang C , Wang J , Xiong J . The role of Axl in drug resistance and epithelial‐to‐mesenchymal transition of non‐small cell lung carcinoma. Int J Clin Exp Pathol 2014; 7: 6653–6661.25400744Wu F , Li J , Jang C , Wang J , Xiong J . The role of Axl in drug resistance and epithelial‐to‐mesenchymal transition of non‐small cell lung carcinoma. Int J Clin Exp Pathol 2014; 7: 6653–6661.25400744, Wu F , Li J , Jang C , Wang J , Xiong J . The role of Axl in drug resistance and epithelial‐to‐mesenchymal transition of non‐small cell lung carcinoma. Int J Clin Exp Pathol 2014; 7: 6653–6661.25400744
-
Min-Hwan Kim: Conceptualization; Methodology -
Timothy D’alfonso, J. Hannah, Zhengming Chen, Yifang Liu, Pengbo Zhou, S. Shin (2014)
Axl receptor tyrosine kinase expression in breast cancerJournal of Clinical Pathology, 67
-
Pyo: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology -
( Blank CU , Rozeman EA , Fanchi LF et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655–1661.30297911)
Blank CU , Rozeman EA , Fanchi LF et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655–1661.30297911Blank CU , Rozeman EA , Fanchi LF et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655–1661.30297911, Blank CU , Rozeman EA , Fanchi LF et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655–1661.30297911
-
( Hugo W , Zaretsky JM , Sun L et al. Genomic and transcriptomic features of response to anti‐PD‐1 therapy in metastatic melanoma. Cell 2016; 165: 35–44.26997480)
Hugo W , Zaretsky JM , Sun L et al. Genomic and transcriptomic features of response to anti‐PD‐1 therapy in metastatic melanoma. Cell 2016; 165: 35–44.26997480Hugo W , Zaretsky JM , Sun L et al. Genomic and transcriptomic features of response to anti‐PD‐1 therapy in metastatic melanoma. Cell 2016; 165: 35–44.26997480, Hugo W , Zaretsky JM , Sun L et al. Genomic and transcriptomic features of response to anti‐PD‐1 therapy in metastatic melanoma. Cell 2016; 165: 35–44.26997480
-
Lijun Zhou, Xian-de Liu, Mianen Sun, Xuesong Zhang, P. Germán, S. Bai, Z. Ding, N. Tannir, C. Wood, S. Matin, J. Karam, P. Tamboli, K. Sircar, P. Rao, E. Rankin, D. Laird, A. Hoang, C. Walker, A. Giaccia, E. Jonasch (2016)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene, 35
-
I. Hasanbasic, J. Cuerquis, B. Varnum, M. Blostein (2004)
Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells.American journal of physiology. Heart and circulatory physiology, 287 3
-
H. Peinado, Haiying Zhang, Irina Matei, B. Costa-Silva, Ayuko Hoshino, G. Rodrigues, B. Psaila, R. Kaplan, J. Bromberg, Yibin Kang, M. Bissell, T. Cox, A. Giaccia, J. Erler, Sachie Hiratsuka, Cyrus Ghajar, D. Lyden (2017)
Pre-metastatic niches: organ-specific homes for metastasesNature Reviews Cancer, 17
-
( Lee WP , Wen Y , Varnum B , Hung MC . Akt is required for Axl‐Gas6 signaling to protect cells from E1A‐mediated apoptosis. Oncogene 2002; 21: 329–336.11821945)
Lee WP , Wen Y , Varnum B , Hung MC . Akt is required for Axl‐Gas6 signaling to protect cells from E1A‐mediated apoptosis. Oncogene 2002; 21: 329–336.11821945Lee WP , Wen Y , Varnum B , Hung MC . Akt is required for Axl‐Gas6 signaling to protect cells from E1A‐mediated apoptosis. Oncogene 2002; 21: 329–336.11821945, Lee WP , Wen Y , Varnum B , Hung MC . Akt is required for Axl‐Gas6 signaling to protect cells from E1A‐mediated apoptosis. Oncogene 2002; 21: 329–336.11821945
-
( Jin G , Wang Z , Wang J et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol Lett 2017; 13: 621–628.28356938)
Jin G , Wang Z , Wang J et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol Lett 2017; 13: 621–628.28356938Jin G , Wang Z , Wang J et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol Lett 2017; 13: 621–628.28356938, Jin G , Wang Z , Wang J et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol Lett 2017; 13: 621–628.28356938
-
P. Elvin, A. Garner (2005)
Tumour invasion and metastasis: challenges facing drug discovery.Current opinion in pharmacology, 5 4
-
Chenjing Zhu, Yu‐quan Wei, Xiawei Wei (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applicationsMolecular Cancer, 18
-
( Graham DK , DeRyckere D , Davies KD , Earp HS . The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014; 14: 769–785.25568918)
Graham DK , DeRyckere D , Davies KD , Earp HS . The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014; 14: 769–785.25568918Graham DK , DeRyckere D , Davies KD , Earp HS . The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014; 14: 769–785.25568918, Graham DK , DeRyckere D , Davies KD , Earp HS . The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014; 14: 769–785.25568918
-
( Reiser J , Banerjee A . Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response. J Immunol Res 2016; 2016: 8941260.27314056)
Reiser J , Banerjee A . Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response. J Immunol Res 2016; 2016: 8941260.27314056Reiser J , Banerjee A . Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response. J Immunol Res 2016; 2016: 8941260.27314056, Reiser J , Banerjee A . Effector, memory, and dysfunctional CD8+ T cell fates in the antitumor immune response. J Immunol Res 2016; 2016: 8941260.27314056
-
Gaoyuan Jin, Zhenzhen Wang, Jianguang Wang, Like Zhang, Yanbin Chen, Pengfei Yuan, Dechun Liu (2016)
Expression of Axl and its prognostic significance in human breast cancerOncology Letters, 13
-
C. Scheele, Carrie Maynard, J. Rheenen (2016)
Intravital Insights into Heterogeneity, Metastasis, and Therapy Responses.Trends in cancer, 2 4
-
Liquan Gao, Chenran Zhang, Duo Gao, Hao Liu, Xinhe Yu, Jianhao Lai, Fan Wang, Jian Lin, Zhaofei Liu (2016)
Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint InhibitionTheranostics, 6
-
( Subramanian M , Hayes CD , Thome JJ et al. An AXL/LRP‐1/RANBP9 complex mediates DC efferocytosis and antigen cross‐presentation in vivo . J Clin Invest 2014; 124: 1296–1308.24509082)
Subramanian M , Hayes CD , Thome JJ et al. An AXL/LRP‐1/RANBP9 complex mediates DC efferocytosis and antigen cross‐presentation in vivo . J Clin Invest 2014; 124: 1296–1308.24509082Subramanian M , Hayes CD , Thome JJ et al. An AXL/LRP‐1/RANBP9 complex mediates DC efferocytosis and antigen cross‐presentation in vivo . J Clin Invest 2014; 124: 1296–1308.24509082, Subramanian M , Hayes CD , Thome JJ et al. An AXL/LRP‐1/RANBP9 complex mediates DC efferocytosis and antigen cross‐presentation in vivo . J Clin Invest 2014; 124: 1296–1308.24509082
-
C. Blank, E. Rozeman, Lorenzo Fanchi, K. Sikorska, B. Wiel, P. Kvistborg, O. Krijgsman, M. Braber, Daisy Philips, A. Broeks, J. Thienen, H. Mallo, S. Adriaansz, S. Meulen, L. Pronk, L. Grijpink-Ongering, A. Bruining, R. Gittelman, S. Warren, H. Tinteren, D. Peeper, J. Haanen, A. Akkooi, T. Schumacher (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanomaNature Medicine, 24
-
( Schmid P , Salgado R , Park YH et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high‐risk, early‐stage triple‐negative breast cancer: results from the phase 1b open‐label, multicohort KEYNOTE‐173 study. Ann Oncol 2020; 31: 569–581.32278621)
Schmid P , Salgado R , Park YH et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high‐risk, early‐stage triple‐negative breast cancer: results from the phase 1b open‐label, multicohort KEYNOTE‐173 study. Ann Oncol 2020; 31: 569–581.32278621Schmid P , Salgado R , Park YH et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high‐risk, early‐stage triple‐negative breast cancer: results from the phase 1b open‐label, multicohort KEYNOTE‐173 study. Ann Oncol 2020; 31: 569–581.32278621, Schmid P , Salgado R , Park YH et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high‐risk, early‐stage triple‐negative breast cancer: results from the phase 1b open‐label, multicohort KEYNOTE‐173 study. Ann Oncol 2020; 31: 569–581.32278621
-
( Peinado H , Zhang H , Matei IR et al. Pre‐metastatic niches: organ‐specific homes for metastases. Nat Rev Cancer 2017; 17: 302–317.28303905)
Peinado H , Zhang H , Matei IR et al. Pre‐metastatic niches: organ‐specific homes for metastases. Nat Rev Cancer 2017; 17: 302–317.28303905Peinado H , Zhang H , Matei IR et al. Pre‐metastatic niches: organ‐specific homes for metastases. Nat Rev Cancer 2017; 17: 302–317.28303905, Peinado H , Zhang H , Matei IR et al. Pre‐metastatic niches: organ‐specific homes for metastases. Nat Rev Cancer 2017; 17: 302–317.28303905
-
( Choi YJ , Kim JH , Rho JK et al. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. Oncol Rep 2017; 37: 2201–2208.28260071)
Choi YJ , Kim JH , Rho JK et al. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. Oncol Rep 2017; 37: 2201–2208.28260071Choi YJ , Kim JH , Rho JK et al. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. Oncol Rep 2017; 37: 2201–2208.28260071, Choi YJ , Kim JH , Rho JK et al. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. Oncol Rep 2017; 37: 2201–2208.28260071
-
(2019)
Data CurationEncyclopedia of Big Data Technologies
-
( Zucca LE , Morini Matushita MA , da Silva Oliveira RJ et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol 2018; 36: 11.e13–e21.)
Zucca LE , Morini Matushita MA , da Silva Oliveira RJ et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol 2018; 36: 11.e13–e21.Zucca LE , Morini Matushita MA , da Silva Oliveira RJ et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol 2018; 36: 11.e13–e21., Zucca LE , Morini Matushita MA , da Silva Oliveira RJ et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol 2018; 36: 11.e13–e21.
- Publisher
- Wiley
- Copyright
- © 2022 Australasian Society for Immunology Inc.
- eISSN
- 2050-0068
- DOI
- 10.1002/cti2.1364
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Clinical & Translational Immunology – Wiley
Published: Jan 1, 2022
Keywords: AXL; immunotherapy; kinase inhibitor; metastasis; small molecule